Autolus Therapeutics (AUTL) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed REGENXBIO (RGNX) over the past year, gaining 0.6% versus a loss of 33.8%. Over five years, AUTL leads with a -71.2% price change compared with -77.5% for RGNX. REGENXBIO is the larger company by market cap ($534.0 million vs $471.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | RGNX |
|---|---|---|
| Share price | $1.77 | $8.09 |
| Market cap | $471.11M | $534.05M |
| 1-day change | -2.21% | +6.52% |
| YTD return | -11.06% | -43.82% |
| 1-year return | +0.57% | -33.80% |
| 5-year return | -71.17% | -77.50% |
| EPS (TTM) | $-1.06 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $16.19 |
| 52-week low | $1.18 | $5.46 |
| Distance from 52-week high | -31.40% | -50.03% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +393.22% | +191.47% |
| Average volume | 2.10M | 1.53M |
| Shares outstanding | 266.16M | 66.01M |
| Employees | 752 | 371 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed RGNX by 34.4 percentage points over the past year.
- The two companies sit in different sectors: Autolus Therapeutics in Health Care and REGENXBIO in Healthcare.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Healthcare · Biotechnology · 371 employees
AUTL vs RGNX FAQ
Which is bigger, Autolus Therapeutics or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $534.05M compared with $471.11M for Autolus Therapeutics (AUTL).
Which stock has performed better over the past year, AUTL or RGNX?
AUTL returned +0.57% over the past 12 months, compared with -33.80% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and REGENXBIO in the same industry?
No. Autolus Therapeutics is in the Health Care sector, while REGENXBIO is in Healthcare.